ArgenX rises on FDA approval for self-administered Vyvgart syringe

argenx SE

11/04/2025 12:35

Updates

** Shares in ArgenX ARGX.BR are up 3.7% after the Belgian biotech company received FDA approval for syringe version of its Vyvgart drug

** U.S.-listed shares of the company ARGX.O also rise 5.1% to $574 premarket

** The pre-filled syringe (PFS) will be self-admin permitted with no specific training nor monitoring required

** "This achievement is expected to get more new patients on drug and help ArgenX achieve its 2030 vision with 50k patients on drug," Degroof Petercam says

** "We see the approval as the next phase in maintaining Vyvgart's launch momentum," KBC analysts say

** Both brokers see around 4% price increase for PFS, which KBC says "should facilitate smooth access under Medicare Part D"

** Brokerage William Blair says "Patients could increase the frequency of dosing given the convenience of self-administration to achieve more continuous symptom relief"

 ** Jefferies expects ARGX will see limited impact from tariffs given U.S. manufacturing footprint from its contract drug manufacturer Lonza LONN.S

** Up to the previous session's close, the shares were down 18.6%​ YTD​

(Reporting by Dimitri Rhodes and Siddhi Mahatole)

((Dimitri.rhodes@thomsonreuters.com))